Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP1 | P07148 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 9/20 | 0.34 |
| ▸ | DRD3 | P35462 | 6/20 | 0.34 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30404831 | 1.00 | FABP1 (0.37) | FABP1PDE4APDE4CPDE4DDRD2 | |
| SCHEMBL29889503 | 0.87 | PDE4A (0.39) | FABP1PDE4APDE4CPDE4DDRD2 | |
| SCHEMBL21315041 | 0.87 | PDE4A (0.39) | FABP1PDE4APDE4CPDE4DDRD2 | |
| SCHEMBL25323447 | 0.86 | FABP1 (0.39) | FABP1PDE4APDE4CPDE4DDRD2 | |
| SCHEMBL21315086 | 0.85 | FABP1 (0.35) | FABP1PDE4APDE4CPDE4DDRD2 | |
| SCHEMBL1249519 | 0.84 | HSD11B1 (0.32) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL26752207 | 0.83 | DRD2 (0.38) | FABP1DRD2DRD3HTR1DDRD4 | |
| SCHEMBL29428689 | 0.83 | DRD2 (0.38) | FABP1DRD2DRD3HTR1DDRD4 | |
| SCHEMBL12856671 | 0.81 | EPAS1 (0.32) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL30919460 | 0.80 | SLC6A2 (0.39) | DRD2DRD3HTR1DDRD4HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11964989-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114615981-B | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116801883-A | Heteroaromatic ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023138583-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230077225-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11453683-B1 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4021444-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FABP1 2426/4885PDE4A 3502/4885PDE4C 3508/4885 |
| US-20230077225-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FABP1 2438/4885PDE4A 3446/4885PDE4C 3456/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FABP1 2508/4885PDE4A 1760/4885PDE4C 1659/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | FABP1 2493/4885PDE4A 3222/4885PDE4C 2449/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | FABP1 3722/4885PDE4A 3558/4885PDE4C 3938/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | FABP1 2493/4885PDE4A 3222/4885PDE4C 2449/4885 |
| US-11964989-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FABP1 1879/4885PDE4A 3474/4885PDE4C 3544/4885 |
| US-11453683-B1 | KRas G12D inhibitors | KRAS, NRAS, HRAS | FABP1 1861/4885PDE4A 3465/4885PDE4C 3527/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | FABP1 2438/4885PDE4A 3446/4885PDE4C 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.